Literature DB >> 10081497

Effect of electroporation on cell killing by boron neutron capture therapy using borocaptate sodium (10B-BSH).

K Ono1, Y Kinashi, S Masunaga, M Suzuki, M Takagaki.   

Abstract

The cell membrane permeability of 10B-enriched borocaptate sodium (BSH) and the extent to which BSH is accumulated in cells are controversial. To elucidate these points and to enhance the accumulation of BSH in cells, the effect of electroporation on boron neutron capture therapy (BNCT) using BSH was investigated. The first group of SCCVII tumor cells was incubated in culture medium with 10B-BSH or 10B-enriched boric acid, and exposed to neutrons from the heavy water facility of the Kyoto University Reactor. More than 99% of neutrons were thermal neutrons at flux base. The second group was pretreated with electroporation in combination with 10B-BSH, and thereafter the cells were irradiated with neutrons. The cell-killing effect of BNCT was measured by colony formation assay. The surviving cell fraction decreased exponentially with neutron fluence, and addition of BSH significantly enhanced the cell-killing effect of NCT depending on 10B concentration and the preincubation time of cells in the BSH-containing culture medium. The electroporation of cells with BSH markedly enhanced the BNCT effect in comparison with that obtained with preincubation alone. The effect of BSH-BNCT with electroporation was almost equal to that of BNCT using 10B-boric acid at the same 10B concentration. The effect of BNCT on cells pretreated with BSH and electroporation was not reduced by repeated washing of the cells before neutron irradiation. Decrease of the effect of BSH-BNCT plus electroporation with increase in the waiting time between the electroporation and the neutron irradiation could be explained in terms of the extent of cell growth during that time. These data suggest that BSH penetrates the cells slowly and remains after washing. Electroporation can introduce BSH into the cells very efficiently, and BSH thus introduced stays in the cells and is not lost in spite of the intensive washing of the cells. Therefore, if electroporation is applied to tumors after BSH injection, 10B would remain in the tumors but be cleared from normal tissues, and selective accumulation of 10B in tumors will be achieved after an appropriate waiting time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10081497      PMCID: PMC5921728          DOI: 10.1111/j.1349-7006.1998.tb00533.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  10 in total

Review 1.  Boron neutron capture therapy of cancer.

Authors:  R F Barth; A H Soloway; R G Fairchild
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

2.  Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds.

Authors:  A H Soloway; H Hatanaka; M A Davis
Journal:  J Med Chem       Date:  1967-07       Impact factor: 7.446

3.  Boron neutron capture therapy: preliminary study of BNCT with sodium borocaptate (Na2B1 2H1 1SH) on glioblastoma.

Authors:  M Takagaki; Y Oda; S Miyatake; H Kikuchi; T Kobayashi; Y Sakurai; M Osawa; K Mori; K Ono
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

4.  Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.

Authors:  N Y Yu; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-08       Impact factor: 7.038

5.  Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy.

Authors:  C P Ceberg; A Brun; L M Mir; B R Persson; L G Salford
Journal:  Anticancer Drugs       Date:  1994-08       Impact factor: 2.248

6.  Boron neutron capture therapy: boron biodistribution and pharmacokinetics of Na2B12H11SH in patients with glioblastoma.

Authors:  K Haselsberger; H Radner; G Pendl
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

7.  Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors.

Authors:  G Stragliotto; H Fankhauser
Journal:  Neurosurgery       Date:  1995-02       Impact factor: 4.654

8.  Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

Authors:  K Ono; S I Masunaga; Y Kinashi; M Takagaki; M Akaboshi; T Kobayashi; K Akuta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-15       Impact factor: 7.038

9.  Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC).

Authors:  M Kambe; N Ioritani; S Shirai; K Kambe; M Kuwahara; D Arita; T Funato; H Shimodaira; M Gamo; S Orikasa; R Kanamaru
Journal:  In Vivo       Date:  1996 May-Jun       Impact factor: 2.155

10.  In vitro determination of uptake, retention, distribution, biological efficacy, and toxicity of boronated compounds for neutron capture therapy: a comparison of porphyrins with sulfhydryl boron hydrides.

Authors:  R G Fairchild; S B Kahl; B H Laster; J Kalef-Ezra; E A Popenoe
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

  10 in total
  2 in total

1.  The combined effect of electroporation and borocaptate in boron neutron capture therapy for murine solid tumors.

Authors:  K Ono; Y Kinashi; M Suzuki; M Takagaki; S I Masunaga
Journal:  Jpn J Cancer Res       Date:  2000-08

2.  The effects of boron neutron capture therapy on liver tumors and normal hepatocytes in mice.

Authors:  M Suzuki; S I Masunaga; Y Kinashi; M Takagaki; Y Sakurai; T Kobayashi; K Ono
Journal:  Jpn J Cancer Res       Date:  2000-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.